Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acadia

- PMLiVE

Healthware Group report on depression care in Italy highlights need for digital therapeutics

Mental health disorders are the fifth leading cause of disability adjusted life years in Italy

- PMLiVE

Mental Health Awareness Week

This year the theme of Mental Health Awareness Week is loneliness, focusing on the impact of it on our mental health and the practical steps we can take to address...

Mednet Group

Supporting Mental Health During a Global Pandemic

Sam Duboc, Chair & CEO of MindBeacon, explores virtual care and telehealth for treating depression, anxiety, addiction, and other conditions; mental health issues brought on by COVID-19; and how to...

Impetus Digital

- PMLiVE

Acadia’s Nuplazid misses the mark in major depressive disorder trial

Company's efforts to extend drug's reach fall flat

Impetus Digital Fireside Chat with with Jon Sockell, Co-Founder/COO of Limbix

Jon Sockell, Co-founder and COO of Limbix, sits down with us in this Fireside Chat. See how Limbix is paving the way for prescription digital therapeutics and learn from their trials,...

Impetus Digital

- PMLiVE

NICE knocks back J&J’s depression nasal spray Spravato

Cites clinical and pricing uncertainty as basis of rejection

- PMLiVE

J&J gets EU approval for depression nasal spray Spravato

Approved with a risk management plan to guard dosing

- PMLiVE

PHARMA CONTENT MARKETING COMES OF AGE – ‘15 MINUTES OF FURY’ A MENTAL HEALTH & SOCIAL MEDIA FILM

A short film which aims to reduce stigma around mental health conversations in underserved grassroots communities in the UK.

Streaming Well

- PMLiVE

Acadia’s drive to extend use of Nuplazid hits a wall

Shares in company down

- PMLiVE

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

CBT-based treatment targets insomnia and depression

- PMLiVE

Sage’s postpartum depression treatment Zulresso gains US approval

First approval of its kind

- PMLiVE

Depression drug failure adds to Allergan’s woes

Axe hangs over remaining monotherapy and suicidality trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links